Add BrightSurf on Google Email

JCI early table of contents for March 19, 2012

Researchers discovered that radiation treatment inhibits monocyte entry into the optic nerve head, preventing neuronal damage in a mouse model of glaucoma. This breakthrough sheds light on a potential prevention strategy for glaucoma, which is one of the leading causes of vision loss and blindness worldwide.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMar 19, 2012

JCI online early table of contents: July 25, 2011

A study by Lukas Van Oudenhove and colleagues found that a fat solution to the stomach attenuates behavioral and nerve cell responses to sad emotion in humans. This discovery has implications for treating disorders such as obesity, eating disorders, and depression. Additionally, two independent research groups have generated new data o...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 25, 2011

New mouse model for testing cancer drugs

Researchers developed a new mouse model to test cancer drugs by simulating gene inhibition, preventing rapid cell division in cancer cells while leaving healthy cells unaffected. The study published in Nature Communications validates the preclinical relevance and predictive value of the inducible RNAi-based mouse model.

SourceGoethe University Frankfurt·JournalNature Communications·DateJul 19, 2011

Cause of hereditary blindness discovered

Researchers from Ruhr-University Bochum discover that mutations in the CCDC66 gene are responsible for retinitis pigmentosa, a leading cause of inherited blindness. They also develop a genetic test for diagnosis and predictively breeding in dogs, with potential implications for human patients.

SourceRuhr-University Bochum·JournalHuman Molecular Genetics·DateJun 22, 2011

Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome

A new study reveals that rapamycin can reverse cardiac muscle damage in a mouse model of LEOPARD syndrome, a rare congenital heart disease. The research demonstrates the importance of targeted therapies in managing congenital diseases and offers a potential new treatment option for patients with LEOPARD syndrome.

SourceBeth Israel Deaconess Medical Center·JournalJournal of Clinical Investigation·DateFeb 21, 2011

Diabetes may clamp down on cholesterol the brain needs

Joslin researchers found that brain cholesterol synthesis decreases in mouse models of diabetes, affecting nerve function and potentially leading to increased appetite and weight gain. The study suggests a link between diabetes and altered brain function, including changes in Alzheimer's disease risk and diabetic neuropathy.

SourceJoslin Diabetes Center·JournalCell Metabolism·DateNov 30, 2010

Diabetes may clamp down on brain cholesterol

Researchers at Joslin Diabetes Center discovered that diabetes can reduce brain cholesterol synthesis, which could impact brain function and increase the risk of Alzheimer's disease. This finding has broad implications for people with diabetes and may also play a role in diabetic neuropathy.

SourceJoslin Diabetes Center·JournalCell Metabolism·DateNov 30, 2010

Signaling hope for polycystic kidney disease

Researchers identify hyperactive c-Met protein as key player in ADPKD cyst growth, leading to potential therapeutic target. Pharmacological inhibition of c-Met decreases mTOR activity and blocks cyst formation in mouse model.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateSep 13, 2010

'TIMely' intervention for asthma

Researchers at Biogen Idec Inc. have found that targeting the TIM-1 protein may be effective in treating asthma. The study used a humanized mouse model to show that an antibody binding to a specific region of TIM-1 reduced inflammation and airway hyperresponsiveness.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 12, 2010

JCI online early table of contents: Feb. 8, 2010

Researchers have identified CD99 as a potential new drug target for Ewing sarcoma. A novel type of cellular senescence has also been found to suppress prostate tumorigenesis. Additionally, the protein USAG-1 has been linked to the development of Alport syndrome, suggesting a promising therapeutic approach.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 8, 2010

Preventing pancreatic islet loss after transplantation

Researchers have identified a potential new set of targets to improve the efficiency of pancreatic islet transplantation. The study found that treatment with an antibody targeting HMGB1 prevented early pancreatic islet loss and inhibited IFN-gamma production by NKT cells and Gr-1+CD11b+ cells.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 1, 2010

Ben-Gurion University Alzheimer's researcher demonstrates specific immune response to vaccine

A team of researchers led by Dr. Alon Monsonego has created a humanized mouse model that responds specifically to an A-beta-peptide vaccine, reducing plaque and inflammation in the brain. The study provides a basis for developing individualized immunotherapeutic approaches to Alzheimer's disease.

SourceAmerican Associates, Ben-Gurion University of the Negev·JournalThe Journal of Immunology·DateSep 21, 2009

JCI online early table of contents: Sept. 1, 2009

Researchers have identified a new mechanism underlying sex-specific gene expression in mice, with PPAR-alpha repressing genes involved in immunity and steroid production. The study also found that this repression is mediated by sumoylation, a process only occurring in female mice, and suggests potential new approaches to prevent estrog...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateSep 1, 2009

Common infant tumor has a Nox(4)ious requirement

Researchers have identified protein Nox4 as crucial for hemangioma growth and found a potent inhibitor fulvene-5 to substantially inhibit its growth. This discovery suggests targeting Nox4 using fulvene derivatives may attenuate hemangioma growth.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 13, 2009